?:authorAffiliation
|
-
[\'Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany. christopher.john.neufeldt@emory.edu.\', \'Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.\', \'BioMed X Institute, BioMed X GmbH, Heidelberg, Germany.\', \'Division Virus-Associated Carcinogenesis, German Cancer Research Center, Heidelberg, Germany.\', \'Division of Signaling and Functional Genomics, German Cancer Research Center, and Department of Cell and Molecular Biology, Heidelberg University, Medical Faculty Mannheim, Mannheim, Germany.\', \'Research Group \'Dynamics of Early Viral Infection and the Innate Antiviral Response\', Division Virus-Associated Carcinogenesis, German Cancer Research Center, Heidelberg, Germany.\', \'Spring Bank Pharmaceuticals, Inc., 35 Corporate Drive, Hopkinton, MA, 01748, USA.\', \'Division of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.\', \'Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany.\', \'Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany. ralf.bartenschlager@med.uni-heidelberg.de.\', \'Division Virus-Associated Carcinogenesis, German Cancer Research Center, Heidelberg, Germany. ralf.bartenschlager@med.uni-heidelberg.de.\', \'German Center for Infection Research, Heidelberg partner site, Heidelberg, Germany. ralf.bartenschlager@med.uni-heidelberg.de.\']
|